Israel · Delayed Price · Currency is ILS · Price in ILA Purple Biotech Company Description
Purple Biotech Ltd., a clinical-stage company, is focused on creating therapies for cancer patients in the United States, specifically addressing challenges like tumor immune evasion and drug resistance.
Its diverse oncology pipeline includes CM24, a humanized monoclonal antibody that targets and blocks carcinoembryonic antigen related cell adhesion molecule 1 (CEACAM1).
Currently in Phase 2 clinical trials, CM24 is being investigated as a combination therapy with anti-PD-1 checkpoint inhibitors for treating pancreatic ductal adenocarcinoma.
Another candidate is NT219, a small molecule compound in Phase 1/2 clinical trials, which functions by inhibiting insulin receptor substrate 1 and 2 (IRS1/2) and signal transducer and activator of transcription (STAT).
This compound is being developed for recurrent and/or metastatic squamous cell carcinoma of the head and neck, or colorectal adenocarcinoma.
Furthermore, IM1240, a multi-valent antibody designed to activate an anti-tumoral immune response against 5T4-positive tumors, is in its preclinical stage.
The company has established significant collaborations, including an agreement with Bristol Myers Squibb Company for Phase 2 clinical trials to assess CM24 in combination with the PD-1 inhibitor nivolumab and chemotherapy, as well as a partnership with Mor Research Applications.
Formerly known as Kitov Pharma Ltd., the company adopted the name Purple Biotech Ltd. in December 2020 and is headquartered in Rehovot, Israel.
| Country | Israel |
| Founded | 1968 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Isaac Israel |
Contact Details
Address: 4 Oppenheimer Street Rehovot, 7670104 Israel | |
| Phone | 972 3 933 3121 |
| Website | purple-biotech.com |
Stock Details
| Ticker Symbol | PPBT |
| Exchange | Tel Aviv Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | IL0007650166 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Shai Lankry CPA, M.B.A. | Chief Financial Officer |
| Dr. Michael Schickler Ph.D. | Head of Clinical and Regulatory Affairs |